ES2966888T3 - Régimen de dosificación para el interferón pegilado - Google Patents
Régimen de dosificación para el interferón pegilado Download PDFInfo
- Publication number
- ES2966888T3 ES2966888T3 ES15857703T ES15857703T ES2966888T3 ES 2966888 T3 ES2966888 T3 ES 2966888T3 ES 15857703 T ES15857703 T ES 15857703T ES 15857703 T ES15857703 T ES 15857703T ES 2966888 T3 ES2966888 T3 ES 2966888T3
- Authority
- ES
- Spain
- Prior art keywords
- interferon
- treatment period
- specifically
- pegylated
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000014150 Interferons Human genes 0.000 title claims description 26
- 108010050904 Interferons Proteins 0.000 title claims description 26
- 229940079322 interferon Drugs 0.000 title claims description 14
- 238000011282 treatment Methods 0.000 claims abstract description 56
- 108010014726 Interferon Type I Proteins 0.000 claims abstract description 26
- 102000002227 Interferon Type I Human genes 0.000 claims abstract description 26
- 208000014767 Myeloproliferative disease Diseases 0.000 claims abstract description 5
- 230000002489 hematologic effect Effects 0.000 claims description 9
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 208000037244 polycythemia vera Diseases 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000005534 hematocrit Methods 0.000 claims description 5
- 238000010606 normalization Methods 0.000 claims description 5
- 238000004820 blood count Methods 0.000 claims description 3
- 229920001427 mPEG Polymers 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 230000004044 response Effects 0.000 description 17
- 229940047124 interferons Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 8
- 229940106366 pegintron Drugs 0.000 description 7
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960003507 interferon alfa-2b Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002435 cytoreductive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 230000006842 hematologic response Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229940002988 pegasys Drugs 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- LICFWYDUJZDCLK-DJNXLDHESA-N (2s)-1-[3,7-bis(2-methoxyethoxycarbonylamino)heptyl]pyrrolidine-2-carboxylic acid Chemical compound COCCOC(=O)NCCCCC(NC(=O)OCCOC)CCN1CCC[C@H]1C(O)=O LICFWYDUJZDCLK-DJNXLDHESA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229950000089 ropeginterferon alfa-2b Drugs 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192114 | 2014-11-06 | ||
| PCT/US2015/059410 WO2016073825A1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2966888T3 true ES2966888T3 (es) | 2024-04-24 |
Family
ID=51945707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15857703T Active ES2966888T3 (es) | 2014-11-06 | 2015-11-06 | Régimen de dosificación para el interferón pegilado |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134260A1 (en) * | 2017-01-18 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| US20230131808A1 (en) * | 2020-04-22 | 2023-04-27 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
| AU2022221496A1 (en) * | 2021-08-29 | 2023-03-16 | Pharmaessentia Corporation | Method of Using Pegylated Interferon-alpha |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| RU2002105485A (ru) * | 1999-08-13 | 2004-01-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) |
| WO2001015736A2 (en) | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
| KR20020065517A (ko) | 1999-11-12 | 2002-08-13 | 맥시겐 홀딩스 리미티드 | 인터페론 감마 접합체 |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| OA13063A (en) | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BRPI0306993B8 (pt) | 2002-01-18 | 2021-05-25 | Biogen Idec Inc | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível |
| US7345150B2 (en) | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
| EP1546235B1 (en) | 2002-09-09 | 2021-10-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| TWI364295B (en) | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| CA2547140A1 (en) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| CN101010105A (zh) | 2004-08-31 | 2007-08-01 | 法玛西雅厄普约翰有限责任公司 | 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 |
| US7365127B2 (en) | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
| EP1869079A2 (en) | 2005-03-11 | 2007-12-26 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101002944B (zh) | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
| EP1834963A1 (en) | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101104078B (zh) | 2006-07-11 | 2011-11-02 | 北京美倍他药物研究有限公司 | 多肽及蛋白药物的聚乙二醇偶合物 |
| CN101108895B (zh) | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| WO2008021487A1 (en) * | 2006-08-18 | 2008-02-21 | Pepgen Corporation | Combination treatment method with interferon-tau |
| CN1966547B (zh) | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
| CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| ES2382124T3 (es) * | 2007-09-04 | 2012-06-05 | Biosteed Gene Expression Tech. Co., Ltd. | Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este |
| CA2698396C (en) | 2007-09-04 | 2014-01-21 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| CN101491682A (zh) | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
| CN102131844B (zh) | 2008-07-31 | 2016-03-02 | 药华医药股份有限公司 | 肽-聚合物缀合物 |
| CN101671390B (zh) | 2008-09-10 | 2012-10-03 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |
| CN101514229B (zh) | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
| UA109646C2 (uk) | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
| CN103328038A (zh) | 2010-12-01 | 2013-09-25 | 史拜诺莫度雷森公司 | 向神经解剖结构直接递送药剂 |
-
2015
- 2015-11-06 JP JP2017519649A patent/JP6820841B2/ja active Active
- 2015-11-06 SM SM20240028T patent/SMT202400028T1/it unknown
- 2015-11-06 SI SI201531980T patent/SI3215193T1/sl unknown
- 2015-11-06 TW TW104136693A patent/TWI737583B/zh active
- 2015-11-06 LT LTEPPCT/US2015/059410T patent/LT3215193T/lt unknown
- 2015-11-06 EP EP15857703.1A patent/EP3215193B1/en active Active
- 2015-11-06 AU AU2015342908A patent/AU2015342908B2/en active Active
- 2015-11-06 KR KR1020237018405A patent/KR102724837B1/ko active Active
- 2015-11-06 BR BR112017009193-3A patent/BR112017009193A2/pt not_active Application Discontinuation
- 2015-11-06 MX MX2017005244A patent/MX389844B/es unknown
- 2015-11-06 UA UAA201705540A patent/UA122867C2/uk unknown
- 2015-11-06 RS RS20231262A patent/RS65015B1/sr unknown
- 2015-11-06 HR HRP20231732TT patent/HRP20231732T1/hr unknown
- 2015-11-06 MY MYPI2017701335A patent/MY191506A/en unknown
- 2015-11-06 HU HUE15857703A patent/HUE064909T2/hu unknown
- 2015-11-06 ES ES15857703T patent/ES2966888T3/es active Active
- 2015-11-06 PH PH1/2017/500617A patent/PH12017500617B1/en unknown
- 2015-11-06 DK DK15857703.1T patent/DK3215193T3/da active
- 2015-11-06 EP EP23199969.9A patent/EP4282485A3/en active Pending
- 2015-11-06 FI FIEP15857703.1T patent/FI3215193T3/fi active
- 2015-11-06 SG SG11201702798PA patent/SG11201702798PA/en unknown
- 2015-11-06 CN CN201580058159.1A patent/CN107530403A/zh active Pending
- 2015-11-06 CA CA2964390A patent/CA2964390A1/en active Pending
- 2015-11-06 NZ NZ730924A patent/NZ730924A/en unknown
- 2015-11-06 EA EA201790991A patent/EA037151B1/ru unknown
- 2015-11-06 HK HK18102667.8A patent/HK1243627A1/zh unknown
- 2015-11-06 WO PCT/US2015/059410 patent/WO2016073825A1/en not_active Ceased
- 2015-11-06 US US15/518,423 patent/US11559567B2/en active Active
- 2015-11-06 KR KR1020177015233A patent/KR102540109B1/ko active Active
- 2015-11-06 PL PL15857703.1T patent/PL3215193T3/pl unknown
- 2015-11-06 PT PT158577031T patent/PT3215193T/pt unknown
-
2017
- 2017-04-06 IL IL251627A patent/IL251627B/en unknown
- 2017-04-18 ZA ZA2017/02704A patent/ZA201702704B/en unknown
- 2017-05-02 CL CL2017001088A patent/CL2017001088A1/es unknown
-
2020
- 2020-09-10 JP JP2020151877A patent/JP2021001184A/ja not_active Withdrawn
-
2022
- 2022-12-23 US US18/088,272 patent/US12343381B2/en active Active
-
2025
- 2025-02-21 US US19/059,883 patent/US20250186552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343381B2 (en) | Dosage regimen for pegylated interferon | |
| Elad et al. | Topical curcumin for the prevention of oral | |
| ES2417061T3 (es) | Formulaciones líquidas de interferón estabilizadas, exentas de hsa | |
| EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| ES2402864T3 (es) | Prevención de infección por VIH con TMC278 | |
| ES2982915T3 (es) | Interferones híbridos para tratar infecciones virales | |
| ES2524454T3 (es) | Formulación líquida de G-CSF | |
| ES2260794T3 (es) | Estimulacion de los mecanismos de defensa del huesped contra los tumores. | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
| WO2022019742A1 (es) | Paquete farmaceutico para prevención y/o tratamiento de enfermedad por covid-19 y uso del mismo | |
| ES2275711T3 (es) | Tratamiento de la hepatitis c con timosina, interferon y ribavirina. | |
| Drozdz et al. | DNA-based delivery of G-CSF as a durable and efficacious approach to treat severe chronic neutropenia | |
| US20250041381A1 (en) | Prophylactic Uses of Theta Defensins | |
| RU2010122438A (ru) | Противовирусное средство для профилактики и лечения клещевого энцефалита | |
| Rizza et al. | Novel HIV drugs and drug delivery strategies. A report from the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA-March 4-7, 2018 | |
| Poordad et al. | Hematologic safety data from the IDEAL trial: neutropenia, anemia, and thrombocytopenia profiles of peginterferon alfa/ribavirin | |
| Hartmann | Feline leukemia virus: still a major cause of death in cats? | |
| Hevorhian et al. | New dental gel" Lizostom": general characteristics, indications for use | |
| Pliner et al. | Cytotoxic Agents and Immune Modulation | |
| RU2009113604A (ru) | Слитые белки альбумина | |
| JP2004143113A (ja) | インターフェロン製剤及びその投与システム |